When compared with the sodiumglucose cotransporter 2 (SGLT2) inhibitors group, the GLP-1RAs group showed no evidence of a difference in terms of new-onset heart failure (HR 0.97
Potential side effects may include temporary water retention, mild joint discomfort, or increased appetite
Recently, FDA assigned has recommended that these peptides should not be made available to the general public because of a lack of evidence
Systemic effects like improved sleep, better mood, increased energy, and enhanced recovery from exercise are well-established at this point
A DNA fragment of ~1,000 bp in length with no target gene was obtained following 2 PCRs
doi: 10.2144/fsoa-2020-0091 210 OrdonezA